US6701002056 - ADR
NOVO-NORDISK A/S-SPONS ADR
NYSE:NVO (9/22/2023, 7:16:28 PM)
After market: 91.53 +0.23 (+0.25%)91.3
+0.01 (+0.01%)
Novo Nordisk A/S is a DK-based company operating in Pharmaceuticals industry. Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
NOVO-NORDISK A/S-SPONS ADR
Novo Alle 1
Bagsvaerd 2880
P: 4544448888.0
CEO: Lars Fruergaard Jorgensen
Employees: 59337
Website: https://www.novonordisk.com/
Treasury yields surged to long-term highs, while leading stocks buckled.
Weight-loss treatments are a big part of Novo Nordisk's business and could be key to its growth for years to come.
In the world of growth stocks, NYSE:NVO shines as a value proposition.
A downbeat analyst take resonated with investors.
The company says it has since corrected the issues found in the FDA inspection.
The good news outweighed the bad for the hot drug developer on Hump Day.
Here you can normally see the latest stock twits on NVO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: